Sun Xiao-fei, Guan Zhong-zhen, Huang He, Zhou Qing-hua, Yi Cheng, Zhang Li-jian, Zhu Jun, Li Rong, Zhou Juan, Zhang Mei, Guo Yin
Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China.
Ai Zheng. 2002 Aug;21(8):892-5.
Cancer chemotherapy can induce thrombocytopenia. It is necessory to develop drugs that can prevent and treat thrombocytopenia. The current study was designed to evaluate the efficacy and toxicity of rhIL-11 in prevention and treatment of chemotherapy-induced thrombocytopenia.
A total of 109 cancer patients were involved randomly into AB or BA group and every patient received 2 cycles of chemotherapy. IL-11 was administered subcutaneously(50 micrograms/kg/d), beginning 24 hours after completion of chemotherapy for 14 consecutive days or continuing until platelet count was > 400 x 10(9)/L during cycle A. Patients did not received IL-11 during cycle B. Another 41 cases of cancer patients whose platelet were less than 50 x 10(9)/L after chemotherapy entered into open study group. IL-11 administration was the same as above.
Efficacy can be evaluated in 107 cases in controlled study group. Mean platelet count of cycle A was (246.49 +/- 88.64) x 10(9)/L and cycle B was (180.24 +/- 83.34) x 10(9)/L(P = 0.000). Grade III/IV thrombocytopenia in cycle A and cycle B were 7/107(6.5%) and 15/107(14%), respectively (P = 0.04). The minimum platelet counts were (136.46 +/- 74.64) x 10(9)/L and (107.77 +/- 61.33) x 10(9)/L, respectively (P = 0.000). The maximum platelet counts were (381.28 +/- 150.39) x 10(9)/L and (207.44 +/- 113.32) x 10(9)/L, respectively (P = 0.000). For open study group, 32 patients could be evaluated. The platelet count increased from(30.1875 +/- 12.13) x 10(9)/L to (226.25 +/- 163.91) x 10(9)/L after IL-11 administration. Major adverse effects were edema, dizziness, palpitation, etc.
rhIL-11 can reduce thrombocytopenia induced by chemotherapy and is a safe and effective drug for treatment of thrombocytopenia.
癌症化疗可导致血小板减少。开发能够预防和治疗血小板减少的药物很有必要。本研究旨在评估重组人白细胞介素-11（rhIL-11）预防和治疗化疗所致血小板减少的疗效及毒性。
109例癌症患者随机分为AB组或BA组，每位患者接受2个周期的化疗。在A周期化疗结束24小时后开始皮下注射IL-11（50微克/千克/天），连续注射14天，或持续至血小板计数>400×10⁹/L。B周期患者不接受IL-11治疗。另外41例化疗后血小板计数低于50×10⁹/L的癌症患者进入开放研究组。IL-11给药方式同上。
对照研究组107例患者可进行疗效评估。A周期平均血小板计数为（246.49±88.64）×10⁹/L，B周期为（180.24±83.34）×10⁹/L（P = 0.000）。A周期和B周期Ⅲ/Ⅳ级血小板减少分别为7/107（6.5%）和15/107（14%）（P = 0.04）。最低血小板计数分别为（136.46±74.64）×10⁹/L和（107.77±61.33）×10⁹/L（P = 0.000）。最高血小板计数分别为（381.28±150.39）×10⁹/L和（207.44±113.32）×10⁹/L（P = 0.000）。开放研究组32例患者可进行评估。注射IL-11后血小板计数从（30.1875±12.13）×10⁹/L升至（226.25±163.91）×10⁹/L。主要不良反应为水肿、头晕、心悸等。
rhIL-11可减轻化疗所致血小板减少，是治疗血小板减少的一种安全有效的药物。
